FYTTD1

Across TCGA pan-cancer cohorts, FYTTD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FYTTD1 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FYTTD1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FYTTD1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where FYTTD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.973	0.219	<.001	33	view →
CCRCC	DFS	Tertile	IV	0.887	0.198	.024	13	view →
LUAD	OS	Median	II,III,IV	1.000	0.433	.005	8	view →
LSCC	DFS	Tertile	II,III,IV	0.529	1.000	.040	1	view →
HNSC	OS	Tertile	All	1.000	0.955	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FYTTD1–PDAC (DFS)

Open the PDAC breakdown →